<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02825134</url>
  </required_header>
  <id_info>
    <org_study_id>H-15019580</org_study_id>
    <nct_id>NCT02825134</nct_id>
  </id_info>
  <brief_title>Comparison of Transcatheter Versus Surgical Aortic Valve Replacement in Younger Low Surgical Risk Patients With Severe Aortic Stenosis</brief_title>
  <acronym>NOTION-2</acronym>
  <official_title>Nordic Aortic Valve Intervention Trial 2 - A Randomized Multicenter Comparison of Transcatheter Versus Surgical Aortic Valve Replacement in Younger Low Surgical Risk Patients With Severe Aortic Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Symetis SA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized clinical trial investigating transcatheter (TAVR) versus surgical (SAVR) aortic
      valve replacement in patients 75 years of age or younger suffering from severe aortic valve
      stenosis.

      Study hypothesis: The clinical outcome (composite endpoint of all-cause mortality, MI and
      stroke) obtained within 1 year after TAVR is non-inferior to SAVR.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND: Acquired aortic valve stenosis (AS) is the most common heart valve disease in the
      Western World with a prevalence of 2-7% at the age of &gt;65 years. If untreated, it may lead to
      heart failure and death. Surgical aortic valve replacement (SAVR) until recent years has been
      the definitive treatment for patients with severe symptomatic AS. A less invasive
      transcatheter aortic valve replacement (TAVR) has been developed and has been a treatment of
      choice mostly for elderly high risk or inoperable patients. As TAVR technology is
      continuously evolving and improving, it may be anticipated that it will become a valuable
      alternative - and even the preferred choice of treatment - for younger, low-risk patients
      with severe aortic valve stenosis in the near future. However, to date, there is no clinical
      evidence that supports this hypothesis.

      AIM: The purpose of the study is to compare TAVR and SAVR with regard to the intra- and
      post-procedural morbidity and mortality rate, hospitalization length, functional capacity,
      quality of life, and valvular prosthesis function in younger, low risk patients with severe
      AS, scheduled for aortic valve replacement.

      POPULATION: Younger low risk patients with severe aortic valve stenosis, which are scheduled
      for aortic valve replacement using a bioprosthesis. Subjects fulfilling the inclusion
      criteria, not having any exclusion criteria, and consenting to the trial will be randomized
      1:1 to TAVR or SAVR with 496 patients in each group.

      DESIGN: The study is a randomized clinical multicenter trial. Central randomization with
      variable block size and stratification by gender and coronary comorbidity will be used. An
      independent event committee blinded to treatment allocation will adjudicate safety endpoints.
      Interim analysis is planned after the first 20 events included in the primary end-point
      (all-cause mortality, stroke or myocardial infarction).

      INTERVENTIONS:

      TAVR: Any CE-Mark approved transcatheter aortic bioprosthesis may be used in the study, and
      the choice is at the discretion of the local TAVR team. The transfemoral TAVR procedure may
      be performed under general anaesthesia, local anaesthesia/conscious sedation, or local
      anesthesia. Percutaneous coronary intervention (PCI) can be performed up to 30 days prior to
      TAVR or as a hybrid procedure.

      SAVR: The surgical SAVR technique follows standard protocol of the local department of
      cardio-thoracic surgery. The operation is performed under general anesthesia, which follows
      standard protocol of the department of anesthesiology. A commercial available surgical aortic
      bioprosthesis at the surgeons discretion will be implanted. Concomitant coronary artery
      bypass graft (CABG) surgery may be performed.

      END POINTS: The primary endpoint is the composite rate of all-cause mortality death,
      myocardial infarction and stroke within one year after the procedure (VARC-2 defintions).
      Secondary endpoints are listed below. Follow-up will be performed after 30 days, 3 months, 1
      year and yearly thereafter for a minimum of 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite rate of all-cause mortality, myocardial infarction and stroke</measure>
    <time_frame>at one year post-procedural.</time_frame>
    <description>VARC-2 definitions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device success (Absence of procedural mortality, correct positioning of a single valve into the proper anatomical location AND intended performanace of the prosthetic heart valve)</measure>
    <time_frame>at 30 days, 1, 2, 3, 4 and 5 years post-procedural.</time_frame>
    <description>VARC-2 definitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure time</measure>
    <time_frame>Intraoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of index hospitalization</measure>
    <time_frame>Number of days from admission to discharge (expected an averge of 7 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite rate of all-cause mortality, myocardial infarction and stroke</measure>
    <time_frame>at 30 days, 2, 3, 4 and 5 years post-procedural.</time_frame>
    <description>VARC-2 definitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>at 30 days, 1, 2, 3, 4 and 5 years post-procedural.</time_frame>
    <description>VARC-2 definitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke or TIA</measure>
    <time_frame>at 30 days, 1, 2, 3, 4 and 5 years post-procedural.</time_frame>
    <description>VARC-2 definitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding (life-threatening, major or minor)</measure>
    <time_frame>at 30 days, 1, 2, 3, 4 and 5 years post-procedural.</time_frame>
    <description>VARC-2 definitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular complication (major or minor)</measure>
    <time_frame>at 30 days, 1, 2, 3, 4 and 5 years post-procedural.</time_frame>
    <description>VARC-2 defintions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute kidney injury (stage 1, 2 or 3)</measure>
    <time_frame>at 30 days, 1, 2, 3, 4 and 5 years post-procedural.</time_frame>
    <description>VARC-2 defintions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic aortic bioprosthesis performance (degree of paravalvular leakage, valve area, mean gradient)</measure>
    <time_frame>Before discharge from index hospitalization (expected an average of 7 days), 3 months, 1, 2, 3, 4 and 5 years post-procedural.</time_frame>
    <description>VARC-2 definitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA functional class</measure>
    <time_frame>at 30 days, 1, 2, 3, 4 and 5 years post-procedural.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for permanent pacemaker</measure>
    <time_frame>at 30 days, 1, 2, 3, 4 and 5 years post-procedural.</time_frame>
    <description>VARC-2 definitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New onset atrial fibrillation captured on ECG</measure>
    <time_frame>Within discharge from index hospitalization (expected an average of 7 days), 30 days, 1, 2, 3, 4 and 5 years post-procedural.</time_frame>
    <description>VARC-2 definitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-related valve safety (echocardiographic structural valve deterioration, prosthetic valve endocarditis, prosthetic valve thrombosis, thrombo-embolic events OR VARC bleeding)</measure>
    <time_frame>at 30 days, 1, 2, 3, 4 and 5 years post-procedural</time_frame>
    <description>VARC-2 definitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricle remodeling as assesed by echocardiography</measure>
    <time_frame>at 30 days, 1, 2, 3, 4 and years post-procedural.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year overall costs in both treatment arms.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of stay on ICU after index procedure.</measure>
    <time_frame>Number of days from procedure to discharge from ICU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of early safety (all-cause mortality, all-stroke, life-threatening bleeding, acute kidney injury, coronary artery obstruction requiring intervention, Major vascular complication OR valve-related dysfunction requiring repeat procedure)</measure>
    <time_frame>at 30 days from index procedure</time_frame>
    <description>VARC-II definitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy (all-cause mortality, all stroke, requiring hospitalization for valve-related symptoms or worsening congestive heart failure, NYHA class III or IV OR echocardiographic valve-related dysfunction)</measure>
    <time_frame>After 30 days of index procedure</time_frame>
    <description>VARC-II definitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life change from baseline</measure>
    <time_frame>at 30 days, 1, 2, 3, 4 and years post-procedural.</time_frame>
    <description>assesed by SF-36v2, EQ-5d and KCCQ</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">992</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Heart Diseases</condition>
  <condition>Heart Valve Diseases</condition>
  <condition>Ventricular Outflow Obstruction</condition>
  <arm_group>
    <arm_group_label>Transcatheter aortic valve replacement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcatheter aortic valve replacement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgical aortic valve replacement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Surgical aortic valve replacement</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter aortic valve replacement</intervention_name>
    <description>Retrograde transfemoral transcatheter aortic valve replacement with any CE mark approved aortic bioprosthesis with or without concomitant percutaneous coronary intervention.</description>
    <arm_group_label>Transcatheter aortic valve replacement</arm_group_label>
    <other_name>Transcatheter aortic valve implantation</other_name>
    <other_name>TAVR</other_name>
    <other_name>TAVI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Surgical aortic valve replacement</intervention_name>
    <description>Conventional surgical aortic valve replacement with a bioprosthesis using normothermic cardiopulmonary bypass and cold blood cardioplegia cardiac arrest with or without concomitant coronary artery bypass graft surgery.</description>
    <arm_group_label>Surgical aortic valve replacement</arm_group_label>
    <other_name>SAVR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 75 years or younger.

          -  Severe aortic stenosis (AS) (valve area &lt;1cm2 or &lt;0.6 cm2/m2), which requires valve
             replacement (symptomatic with angina pectoris, dyspnea or exercise-induced syncope or
             near syncope OR asymptomatic with abnormal exercise test showing symptoms on exercise
             clearly related to AS or systolic LV dysfunction (LVEF &lt;50%) not due to another
             cause.)

          -  Anticipated usage of biological aortic valve prosthesis.

          -  Low risk for conventional surgery (STS Score &lt;4%).

          -  Suitable for both SAVR and transfemoral TAVR.

          -  Life expectancy &gt;1 year after the intervention.

          -  Informed consent to participate in the study after adequate information about the
             study before randomization and intervention.

        Exclusion Criteria:

          -  Coronary artery disease, not suitable for both percutaneous coronary intervention
             (PCI) or coronary artery bypass graft surgery (CABG).

          -  LVEF &lt;25% without contractile reserve during dobutamine stress echocardiography.

          -  Porcelain aorta, which prevents open-heart surgery.

          -  Bicuspid valve with aorta ascendens diameter ≥45mm

          -  Severe femoral, iliac or aortic atherosclerosis, calcification, coarctation, aneurysm
             or tortuosity, which prevents transfemoral TAVR.

          -  Need for open heart surgery other than SAVR with or without CABG.

          -  Myocardial infarction within last 30 days OR percutaneous coronary intervention
             requiring dual antiplatelet therapy within last six months.

          -  Coronary angiogram with a SYNTAX-score &gt;22.

          -  Previous open-heart surgery or previous mediastinal radiation therapy.

          -  Stroke or TIA within the last 30 days.

          -  Current endocarditis, intracardiac tumor, thrombus or vegetation.

          -  Ongoing severe infection requiring intravenous antibiotics.- Unstable pre-procedural
             condition requiring intravenous inotropes or mechanical assist device (IABP, Impella)
             on the day of intervention.

          -  Kidney disease requiring dialysis or severely impaired lung function (FEV1 and/or
             diffusion capacity &lt;40% of predicted).

          -  Allergy to heparin, iodid contrast agent, warfarin, aspirin or clopidogrel.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Søndergaard, MD; DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter S Olsen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lars Søndergaard, MD; DMSc</last_name>
    <email>Lars.Soendergaard.01@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rigshospitalet, Copenhagen University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Søndergaard</last_name>
      <email>Lars.Soendergaard.01@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Peter S Olsen</last_name>
      <email>Peter.Skov.Olsen@regionh.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Henrik Nissen</last_name>
      <email>henrik.nissen@rsyd.dk</email>
    </contact>
    <contact_backup>
      <last_name>Bo Kjeldsen</last_name>
      <email>bo.kjeldsen@rsyd.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Ålborg</city>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jan Ravnkilde</last_name>
      <email>jan.ravkilde@rn.dk</email>
    </contact>
    <contact_backup>
      <last_name>Jørn Sollid</last_name>
      <email>joas@rn.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Aarhus University hospital</name>
      <address>
        <city>Århus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Evald H Christiansen</last_name>
      <email>evalchri@rm.dk</email>
    </contact>
    <contact_backup>
      <last_name>Kaj Erik Klaaborg</last_name>
      <email>kajklaab@rm.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>FI00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mika Laine</last_name>
      <email>mika.laine@hus.fi</email>
    </contact>
    <contact_backup>
      <last_name>Leo Ihlberg</last_name>
      <email>leo.ihlberg@hus.fi</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <zip>70210</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heikki Miettinen</last_name>
      <email>heikki.miettinen@kuh.fi</email>
    </contact>
    <contact_backup>
      <last_name>Martin Maaroos</last_name>
      <email>martin.maaroos@kuh.fi</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Timo Mäkikallio</last_name>
      <email>timo.makikallio@ppshp.fi</email>
    </contact>
    <contact_backup>
      <last_name>Vesa Anttila</last_name>
      <email>vesa.anttila@ppshp.fi</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Markku Eskola</last_name>
      <email>markku.eskola@sydansairaala.fi</email>
    </contact>
    <contact_backup>
      <last_name>Pasi Maaranen</last_name>
      <email>pasi.maaranen@sydanairaala.fi</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mikko Savotaus</last_name>
      <email>mikko.savontaus@tyks.fi</email>
    </contact>
    <contact_backup>
      <last_name>Markus Malmberg</last_name>
      <email>markus.malmberg@tyks.fi</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Landspital</name>
      <address>
        <city>Reykjavík</city>
        <zip>101</zip>
        <country>Iceland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ingibjörg J Gudmundsdóttir</last_name>
      <email>ig@landspitali.is</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Öjvind Bleie</last_name>
      <email>oyvind.bleie@helse-bergen.no</email>
    </contact>
    <contact_backup>
      <last_name>Rune Haaverstad</last_name>
      <email>rune.haaverstad@helse-bergen.no</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Feiring Klinikkene</name>
      <address>
        <city>Feiring</city>
        <zip>2093</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yngvar Myreng</last_name>
      <email>yngvar.myreng@feiringklinikken.no</email>
    </contact>
    <contact_backup>
      <last_name>Stein-Erik Rynning</last_name>
      <email>stein.rynning@feiringklinikken.no</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>2009</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lars Aaberge</last_name>
      <email>laraabe@ous-hf.no</email>
    </contact>
    <contact_backup>
      <last_name>Kjell-Arne Rein</last_name>
      <email>kjrein@ous-hf.no</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Norway</name>
      <address>
        <city>Tromsø</city>
        <zip>9019</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Terje Steigen</last_name>
      <email>terje.steigen@unn.no</email>
    </contact>
    <contact_backup>
      <last_name>Rolf Busund</last_name>
      <email>rolf.busund@unn.no</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>St. Olav's University Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7030</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Knut Hegbom</last_name>
      <email>knut.hegbom@stolav.no</email>
    </contact>
    <contact_backup>
      <last_name>Peder Kvitting</last_name>
      <email>peder.kvitting@helse-bergen.no</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Göteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Truls Råmunddal</last_name>
      <email>Truls.Ramunddal@wlab.gu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <zip>581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Niels Erik Nielsen</last_name>
      <email>niels-erik.nielsen@regionostergotland.se</email>
    </contact>
    <contact_backup>
      <last_name>Henrik Ahn</last_name>
      <email>henrik.ahn@regionostergotland.se</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>222 41</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthias Götberg</last_name>
      <email>matthias.gotberg@skane.se</email>
    </contact>
    <contact_backup>
      <last_name>Henrik Bjursten</last_name>
      <email>henrik.bjursten@skane.se</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andreas Rück</last_name>
      <email>andreas.ruck@karolinska.se</email>
    </contact>
    <contact_backup>
      <last_name>Göran Källner</last_name>
      <email>goran.kallner@karolinska.se</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University hospital of Umeå</name>
      <address>
        <city>Umeå</city>
        <zip>901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Johan Nilsson</last_name>
      <email>johan.nilsson@vll.se</email>
    </contact>
    <contact_backup>
      <last_name>Anne-Marie N Grenholm</last_name>
      <email>annemarie.grenholm@vll.se</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan James</last_name>
      <email>stefan.james@ucr.uu.se</email>
    </contact>
    <contact_backup>
      <last_name>Anders Jönsson</last_name>
      <email>anders.jonsson@ucr.uu.se</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Örebro University Hospital</name>
      <address>
        <city>Örebro</city>
        <zip>701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Kellerth</last_name>
      <email>thomas.kellerth@orebroll.se</email>
    </contact>
    <contact_backup>
      <last_name>Örjan Friberg</last_name>
      <email>orjan.friberg@orebroll.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Iceland</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2016</study_first_submitted>
  <study_first_submitted_qc>July 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2016</study_first_posted>
  <last_update_submitted>July 3, 2016</last_update_submitted>
  <last_update_submitted_qc>July 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Lars Soendergaard</investigator_full_name>
    <investigator_title>Professor of cardiology Lars Søndergaard; MD, DMSc</investigator_title>
  </responsible_party>
  <keyword>heart valve disease</keyword>
  <keyword>valvular bioprosthesis</keyword>
  <keyword>aortic valve replacement</keyword>
  <keyword>Randomized clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
    <mesh_term>Ventricular Outflow Obstruction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

